TABLE 1.
Patients’ characteristics.
| Parameter | HL (n = 24) |
|---|---|
| Male/female; no | 17/7 |
| Median age at diagnosis; (years, range) | 24 (15–41) |
| Histology subtype at diagnosis; no, % | |
| Nodular sclerosis | 19 (80) |
| Mixed cellularity | 5 (20) |
| Ann Arbor stage; no, % | |
| II | 9 (38) |
| III | 8 (33) |
| IV | 7 (29) |
| B symptoms; no, % | 14 (58) |
| First-line chemotherapy; n, % | |
| ABVD | 15 (63) |
| MOPP | 4 (17) |
| BEACOPP | 4 (17) |
| ESHAP | 1 (3) |
| Median number of treatment lines; n, range | 5 (3–10) |
| Radiotherapy prior to transplantation; n, % | 20 (83) |
| ASCT1; n, % | 20 (83) |
| ASCT2; n,% | 8 (33) |
| Median time from diagnosis to ASCT1; (months, range) | 18.3 (9.5–71.1) |
| Median time from ASCT1 to ASCT2; (months, range) | 17.6 (1.7–34.6)* |
| Median time from diagnosis to allo-SCT; (years, range) | 3.97 (1.31–10.8) |
| Median time from ASCT1 to allo-SCT; (months, range;) | 17.1 (3.6–68.0) # |
allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; HL, Hodgkin lymphoma; *n = 8; #n = 20.